Table 1.

Overview of High-Dose BoNTA Studies

Product	Placebo controlled (Y/N)	Maximum dose (X registration dose)	Duration	Volume per injection	Dose studied	Primary endpoint
Abobotulinum (N = ~400)	Yes	2.5	36 weeks (~252 days)	0.05 mL	50U (US label), 75U, 100U, and 125U	Composite response at 30 days (investigator AND patient both report a score of ≤1 in glabellar line severity AND ≥2-grade improvement from baseline)
Incobotulinum (N = 151)	No	3.75	180 days (~28 weeks)	0.05 mL	20U (US label), 50U, and 75U	Return to baseline severity
Onabotulinum (N = 225)	Yes	4.0	48 weeks (336 days)	0.05 mL	20U (US label), 40U, 60U, and 80U	Proportion with ≥1-grade improvement from baseline at week 24 (investigator)

BoNTA, botulinum neurotoxin type A.